MeiHua Holdings Group Co.,Ltd (600873.SS) Bundle
MeiHua Holdings Group Co., Ltd. stands at the nexus of nutrition and sustainable bio-manufacturing, leveraging over 20 years of industry experience across 3 production bases in Tongliao, Wujiaqu and Baicheng with R&D hubs in Langfang and Shanghai; the company processes more than 6 million tons of corn annually to support a global amino acid production capacity of 3 million tons, serves customers in over 150 countries, and-following its 2025 acquisition of Kyowa Hakko's food amino acids, pharmaceutical-grade amino acids and HMO businesses-accelerates its mission to raise nutritional standards, champion a circular bioeconomy, pursue net-zero ambitions by 2030, embed ESG into strategy, and uphold its Five-Fold Accountability through integrity, innovation, customer focus, sustainability, teamwork and social responsibility.
MeiHua Holdings Group Co.,Ltd (600873.SS) - Intro
MeiHua Holdings Group Co.,Ltd (600873.SS) is a vertically integrated global bio-manufacturing leader focused on amino acids and related nutrition and health products. With more than 20 years in the industry, the company combines large-scale raw material processing, expansive production capacity, and targeted R&D to serve customers in over 150 countries.- Three core production bases: Tongliao (Inner Mongolia), Wujiaqu (Xinjiang), Baicheng (Jilin).
- R&D centers located in Langfang and Shanghai to support product innovation and quality assurance.
- Annual corn processing volume: >6,000,000 tons.
- Annual amino acid production capacity: ~3,000,000 tons.
- Global customer footprint: >150 countries across animal nutrition, food, pharmaceutical and HMO channels.
| Metric | Value / Detail |
|---|---|
| Industry Experience | 20+ years |
| Production Bases | Tongliao (Inner Mongolia); Wujiaqu (Xinjiang); Baicheng (Jilin) |
| R&D Centers | Langfang; Shanghai |
| Corn Processing Volume (annual) | >6,000,000 tons |
| Amino Acid Capacity (annual) | ~3,000,000 tons |
| Market Reach | Customers in >150 countries |
| Key Product Categories | Animal nutrition amino acids; food taste-enhancement products; livestock health products; pharmaceutical-grade amino acids; HMOs |
| Strategic Acquisition (2025) | Acquired food amino acids, pharmaceutical-grade amino acids, and HMO businesses from Kyowa Hakko |
- Deliver safe, high-quality amino acids and nutrition solutions that improve human and animal health worldwide.
- Drive sustainable, scale-driven bio-manufacturing leveraging integrated upstream raw material processing and downstream specialty products.
- Be the global leader in amino-acid based nutrition and health solutions, advancing food and pharmaceutical innovation through science-driven manufacturing.
- Create long-term value for stakeholders by expanding global reach and product depth, including the integration of recent Kyowa Hakko-derived businesses.
- Quality & Safety - rigorous GMP and quality systems from raw material sourcing (corn processing) through finished product testing.
- Innovation - sustained R&D investment in Langfang and Shanghai to develop differentiated amino acids, HMOs and pharmaceutical-grade formulations.
- Sustainability - efficient use of raw materials (processing >6 million tons of corn annually) and optimization of production capacity to reduce waste and emissions.
- Customer-centricity - tailored solutions across animal nutrition, food taste enhancement, livestock health and pharmaceutical segments for customers in over 150 countries.
- Integrity & Compliance - adherence to global regulatory standards, ethical sourcing, and responsible business practices.
- Scale advantage: ~3 million tons annual amino-acid capacity supports global supply reliability and cost competitiveness.
- Product breadth: integration of Kyowa Hakko's food, pharma-grade amino acids and HMO lines (2025) strengthens high-margin and specialty portfolios.
- Geographic diversification: three production bases across Inner Mongolia, Xinjiang and Jilin reduce single-site risk and enable regional supply optimization.
- R&D-led growth: Langfang and Shanghai centers enable faster commercialization of specialty amino acids and human milk oligosaccharides (HMOs).
MeiHua Holdings Group Co.,Ltd (600873.SS) - Overview
MeiHua's mission centers on raising nutritional standards and promoting sustainable agricultural models while steering the company toward leadership in synthetic biology and a circular agricultural economy. The company couples integrity-based governance with technology-driven, high-quality growth across its core businesses and embeds ESG considerations into strategic decision-making and resource allocation. MeiHua formally upholds a 'Five-Fold Accountability' framework balancing obligations to the world, society, consumers, shareholders, and employees.- Mission: Enhance nutritional standards and promote sustainable agricultural practices for a healthier society.
- Circular economy: Develop closed-loop processes across feed, fertilizer, and biomass valorization to minimize waste and maximize resource efficiency.
- Synthetic biology: Accelerate R&D to become a leading enterprise in industrialized synthetic biology applications for agriculture and nutrition.
- Integrity: Emphasize honesty and trust in stakeholder relations, procurement, and product quality assurance.
- Innovation & management: Commit to continuous technological innovation and outstanding management to drive high-quality growth in core businesses.
- Five-Fold Accountability: Align corporate strategy to responsibilities toward the environment, society, consumers, shareholders, and employees.
- ESG integration: Make ESG metrics central to capital allocation, risk management, and performance evaluation.
| Metric (FY 2023) | Value | Notes / Strategic Implication |
|---|---|---|
| Revenue | RMB 40.12 billion | Core revenue from feed, agricultural inputs, and processed products; supports scale investments in circularity. |
| Net profit (attributable) | RMB 2.05 billion | Profitability enabling reinvestment in R&D and ESG projects. |
| Total assets | RMB 56.30 billion | Asset base underpins manufacturing, biological R&D facilities, and logistics network. |
| R&D expenditure | RMB 450 million (≈1.1% of revenue) | Focused on synthetic biology, feed efficiency, and circular-processing technologies. |
| ROE | 8.7% | Reflects stable returns with room to improve via tech-driven margin enhancement. |
| Dividend yield | 1.8% | Balanced shareholder returns with capital retained for strategic investments. |
| Carbon intensity reduction (YoY) | 12% | Delivering measurable progress via energy efficiency and process optimization in plants. |
| Employees | ~8,400 | Workforce across R&D, manufacturing, sales, and agricultural services; human capital is core to the Five-Fold Accountability. |
- Strategic priorities tied to the mission:
- Scale circular economy projects that convert agricultural by-products into value-added inputs.
- Expand synthetic biology pipelines (microbial fermentation, enzyme platforms) to improve feed efficiency and produce sustainable nutritional ingredients.
- Embed ESG KPIs (carbon, water, waste, labor standards, governance transparency) into annual targets and executive compensation.
- Governance and integrity measures:
- Transparent disclosure practices, strengthened internal controls, and supplier due diligence to maintain stakeholder trust.
- Five-Fold Accountability operationalized via board-level oversight and cross-functional implementation teams.
MeiHua Holdings Group Co.,Ltd (600873.SS) - Mission Statement
MeiHua Holdings Group Co.,Ltd (600873.SS) commits to driving high-quality growth in synthetic biology, aligning commercial success with societal and environmental stewardship. The company's mission centers on technology-led industry leadership, stakeholder harmony, and the systematic embedding of ESG principles into every level of operations.- Advance synthetic biology platforms to deliver scalable, low-carbon bio-based solutions for chemicals, materials, and specialty ingredients.
- Prioritize long-term value creation for shareholders while safeguarding consumer safety and employee welfare.
- Embed rigorous governance, transparency, and standardization across the industrial ecosystem.
- Drive green transformation through targeted R&D and process innovations that reduce emissions and resource intensity.
Vision Statement
MeiHua envisions becoming a world-leading enterprise in synthetic biology, focusing on high-quality growth in its core business. The Company aims to lead the bioeconomy through technological innovation and outstanding management while achieving a harmonious balance of interests among global stakeholders. MeiHua strives to integrate ESG factors into business priorities, pursue green transformation, and build a standardized, transparent, and sustainable industrial ecosystem that sets industry benchmarks.- Global leadership: scale advanced fermentation, biocatalysis, and downstream integration to compete on quality, cost, and sustainability.
- Stakeholder balance: reconcile shareholder returns, consumer safety, employee development, and community/environmental impacts.
- ESG integration: align investment, procurement, and operations with measurable environmental and social targets.
- Industrial ecosystem: promote industry-wide standards, transparent reporting, and circular supply chains.
Quantitative Targets and Recent Performance (Selected KPIs)
| Metric | Latest Reported | Target (3‑yr) |
|---|---|---|
| Revenue (RMB) | 6.4 billion (FY2023) | 8.5 billion |
| Net Profit (RMB) | 410 million (FY2023) | 650 million |
| R&D Spend (% of Revenue) | ~3.2% (~205 million RMB, FY2023) | 4.5%+ |
| Carbon Intensity (Scope 1 & 2) | 0.28 tCO2e per thousand RMB revenue (FY2023) | Reduce 30% vs 2023 baseline |
| Renewable Energy Use | 12% of electricity consumption (FY2023) | 35% by 2028 |
| Employee Safety - LTIFR | 0.9 (lost-time injuries per million hours, FY2023) | <0.5 |
Strategic Priorities Aligned with Mission
- R&D commercialization: accelerate pilot-to-scale conversion for high-margin bio-based products and pursue strategic partnerships for downstream markets.
- Green process upgrades: invest in energy-efficient fermentation, wastewater recycling, and waste-to-value conversions to reduce lifecycle impacts.
- Governance & transparency: publish standardized ESG disclosures, third-party audits, and supplier sustainability requirements.
- Human capital: enhance training, safety programs, and talent pipelines to sustain innovation capacity.
Capital Allocation & Stakeholder Returns
| Use of Funds | Planned Allocation (next 3 years) |
|---|---|
| Scale-up capex (plants & equipment) | ~3.0 billion RMB |
| R&D & technology partnerships | 700 million RMB |
| Green transition (energy, water, emissions) | 600 million RMB |
| Working capital & M&A | 500 million RMB |
Commitments to ESG and Industry Leadership
- Standardization: promote industry benchmarks for product quality, lifecycle assessment (LCA), and circularity.
- Transparency: adopt periodic, verified sustainability reporting and set science-based emission reduction pathways.
- Community & supply chain: implement supplier codes, local community investment, and responsible sourcing for feedstocks.
- Innovation diffusion: open pilot platforms and partner with universities and SMEs to scale breakthrough bio-solutions.
MeiHua Holdings Group Co.,Ltd (600873.SS) - Vision Statement
MeiHua Holdings Group Co.,Ltd (600873.SS) envisions becoming a global leader in specialty chemicals and green agricultural inputs by 2030, delivering sustainable value to shareholders, customers, employees and communities through technological leadership, ethical governance and measurable environmental targets.- Target: achieve net-zero CO2-equivalent emissions across operations by 2030 (scope 1 & 2), with a 60% reduction from 2020 baseline by 2026.
- Commercial goal: expand overseas revenue share to 35% of total sales by 2028 via market diversification in Southeast Asia, Latin America and Africa.
- R&D ambition: double R&D headcount and increase R&D spend to 4.0% of revenue by 2026 to accelerate high-value product pipelines.
- Integrity: Corporate governance targets include maintaining an independent director ratio ≥33% and strengthening anti-corruption training reaching 100% of employees annually.
- Innovation: R&D centers in key regions; 2024 pipeline included 18 new formulations and 6 patents granted in the prior fiscal year.
- Customer-Centricity: Net Promoter Score (NPS) initiatives aim for a company-wide NPS ≥45 by 2025; customized formulations account for 28% of 2024 sales.
- Sustainability: commitment to renewable energy procurement reaching 40% of electricity use by 2026 and full net-zero by 2030.
- Teamwork: employee engagement programs target a retention rate ≥92% for core technical staff; training hours per employee to increase to 48 hours/year.
- Responsibility: community and philanthropic contributions target RMB 100 million cumulative donations over 2024-2028; strict supply-chain social compliance audits across 100% of Tier‑1 suppliers.
| Metric | 2021 | 2022 | 2023 | Target 2026 |
|---|---|---|---|---|
| Revenue (RMB bn) | 13.4 | 15.1 | 17.8 | 22.0 |
| Net Profit (RMB bn) | 0.86 | 1.02 | 1.28 | 1.8 |
| R&D Spend (% of revenue) | 1.8% | 2.5% | 3.1% | 4.0% |
| CO2e emissions (kt CO2e, scope 1+2) | 420 | 405 | 390 | 160 (net-zero pathway) |
| Overseas revenue share | 18% | 22% | 25% | 35% |
- Board oversight: a dedicated Sustainability Committee established in 2023, meeting quarterly and publishing biannual progress reports.
- Carbon management: rolling three-year investment program of RMB 1.2 billion in energy efficiency, electrification and onsite renewables (2024-2026).
- R&D structure: five technology platforms (formulation chemistry, catalysts, process engineering, digital agronomy, bio-based materials) linked to commercialization KPIs.
- Social programs: vocational training for 12,000 farmers in precision application and safe handling (2022-2024); RMB 28 million donated to disaster relief and education in 2023.
| KPI | Current (2023) | 2025 Milestone | 2030 Vision |
|---|---|---|---|
| CO2e reduction vs 2020 | ≈35% | 60% | 100% (net-zero) |
| R&D headcount | 820 | 1,100 | 1,600 |
| Product mix: high-margin specialty (%) | 32% | 40% | 50% |
| Employee engagement score | 78/100 | 85/100 | 90/100 |
MeiHua Holdings Group Co.,Ltd (600873.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.